Klow 80mg: Safety Profile & Research Summary
Preclinical Research Summary (Component-Level)
No peer-reviewed studies have evaluated the KLOW 50/10/10/10 blend as a co-administered formulation. Component-level research is summarized below; for full data see the dedicated GHK-Cu, BPC-157, TB-500, and KPV entries.
| Component | Representative Study | Key Finding |
|---|---|---|
| GHK-Cu | Pickart & Margolina (2018) | Modulates >4,000 genes; resets expression toward "younger" state |
| BPC-157 | Hsieh et al. (2017) | 129–152% increased angiogenesis via VEGFR2-Akt-eNOS |
| TB-500 | Philp et al. (2003) | LKKTETQ promoted dermal repair comparable to full Tβ4 |
| KPV | Dalmasso et al. (2008) | PepT1-mediated KPV uptake reduces intestinal NF-κB inflammation |
| KPV | Kannengiesser et al. (2008) | Anti-inflammatory potential in murine IBD models |
| KPV | Xiao et al. (2017) | 12,000-fold potency increase via HA-functionalized nanoparticle delivery |
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences. 2018;19(7):1987.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways. BioMed Research International. 2015;2015:648108.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Dalmasso G, et al. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding. FDA.gov. Updated 2023.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. Journal of Molecular Medicine. 2017;95(3):323-333.
- Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development. 2004;125(2):113-115.
- Brzoska T, et al. α-Melanocyte-Stimulating Hormone and Related Tripeptides. Endocrine Reviews. 2008;29(5):581-602.
- Park JR, et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury. Oncotarget. 2016;7(36):58405-58417.
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157. Current Neuropharmacology. 2016;14(8):857-865.
- Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites. Journal of Chromatography B. 2024;1235:124033.
- Kannengiesser K, et al. KPV has anti-inflammatory potential in murine IBD models. Inflammatory Bowel Diseases. 2008;14(3):324-331.
- Xiao B, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles. Molecular Therapy. 2017;25(7):1628-1640.
Related Research Questions
Want the complete research review?
View Full Klow 80mg Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.